Abstract Background The Infectious Diseases Society of America (IDSA) is committed to
providing up-to-date guidance on the treatment of antimicrobial-resistant (AMR) infections …

Therapy of invasive infections due to multidrug-resistant Enterobacteriaceae (MDR-E) is
challenging, and some of the few active drugs are not available in many countries. For …

Abstract Background The Infectious Diseases Society of America (IDSA) is committed to
providing up-to-date guidance on the treatment of antimicrobial-resistant infections. The …

Urinary tract infections (UTIs) are one of the most common pathological conditions in both
community and hospital settings. It has been estimated that about 150 million people …

Scope These ESCMID guidelines address the targeted antibiotic treatment of third-
generation cephalosporin-resistant Enterobacterales (3GCephRE) and carbapenem …

The in vitro susceptibility testing interpretive criteria (STIC) for piperacillin/tazobactam (TZP)
against Enterobacterales were recently updated by the US Food and Drug Administration …

Introduction Complicated urinary tract infections (cUTIs) entail diverse clinical conditions that
could be managed differently and not necessarily with premature empiric therapy. Since …

The increasing incidence of infections caused by extended-spectrum beta-lactamase
(ESBL)/AmpC-producing bacteria leads to increasing use of carbapenems and risk of …

Background It is important for intensivists to understand inducible AmpC b-lactamase
production, and when to consider it in making treatment decisions. Inducible expression of …

This systematic review was conducted to compare the efficacy of non-carbapenem β-
lactam/β-lactamase inhibitors (BLBLIs) versus carbapenems for the treatment of urinary tract …